Systematic Reviews
Copyright ©The Author(s) 2015.
World J Clin Oncol. Aug 10, 2015; 6(4): 64-72
Published online Aug 10, 2015. doi: 10.5306/wjco.v6.i4.64
Table 3 Incidence of adverse events attributable to abiraterone in the pre- and post-chemotherapy settings
Adverse eventsPre-chemotherapyincidence (95%CI)Post-chemotherapyincidence (95%CI)
Cardiac disorders all-grade3.0% (1.9%-4.8%)4.0% (2.8%-5.6%)
Fluid retention and edema all-grade4.0% (2.6%-6.0%)9.0% (7.2%-11.2%)b
Hypertension all-grade9.0% (6.9%-11.7%)3.0% (2.0%-4.4%)b
Hypokalemia all-grade9.0% (7.2%-11.2%)4.0% (2.6%-6.0%)b
Hypokalemia high-grade0.1% (1.0%-1.5%)3.7% (2.6%-5.2%)b